One-Year Treatment With Exenatide Improves β-Cell Function, Compared With Insulin Glargine, in Metformin-Treated Type 2 Diabetic Patients
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Traditional blood glucose–lowering agents do not sustain adequate glycemic control in most type 2 diabetic patients. Preclinical studies with exenatide have suggested sustained improvements in β-cell function. We investigated the effects of 52 weeks of treatment with exenatide or insulin glargine followed by an off-drug period on hyperglycemic clamp–derived measures of β-cell function, glycemic control, and body weight. RESEARCH DESIGN AND METHODS: Sixty-nine metformin-treated patients with type 2 diabetes were randomly assigned to exenatide (n = 36) or insulin glargine (n = 33). β-Cell function was measured during an arginine-stimulated hyperglycemic clamp at week 0, at week 52, and after a 4-week off-drug period. Additional end points included effects on glycemic control, body weight, and safety. RESULTS: Treatment-induced change in combined glucose- and arginine-stimulated C-peptide secretion was 2.46-fold (95% CI 2.09–2.90, P < 0.0001) greater after a 52-week exenatide treatment compared with insulin glargine treatment. Both exenatide and insulin glargine reduced A1C similarly: −0.8 ± 0.1 and −0.7 ± 0.2%, respectively (P = 0.55). Exenatide reduced body weight compared with insulin glargine (difference −4.6 kg, P < 0.0001). β-Cell function measures returned to pretreatment values in both groups after a 4-week off-drug period. A1C and body weight rose to pretreatment values 12 weeks after discontinuation of either exenatide or insulin glargine therapy. CONCLUSIONS: Exenatide significantly improves β-cell function during 1 year of treatment compared with titrated insulin glargine. After cessation of both exenatide and insulin glargine therapy, β-cell function and glycemic control returned to pretreatment values, suggesting that ongoing treatment is necessary to maintain the beneficial effects of either therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Recently, early interventions with insulin therapy in newly diagnosed T2D ( 83 ), with targeted anti-inflammatory therapy using an IL-1β antagonist ( 84 ), and with GLP-1 receptor agonists ( 85 ) have demonstrated that β-cell dysfunction can be reversed temporarily.”
From β-Cell Failure in Type 2 Diabetes: Postulated Mechanisms and Prospects for Prevention and Treatment (2014) · cites this paper as [85]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The metabolic phenotype in obesity: Fat mass, body fat distribution, and adipose tissue function
Goossens, G. H. (2017) · Obesity Facts · doi:10.1159/000471488 · Cited by 8,481
Glucose clamp technique: a method for quantifying insulin secretion and resistance.
DeFronzo, R. A., Tobin, J. D., & Andres, R. (1979) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1979.237.3.e214 · Cited by 7,425
The biology of incretin hormones
Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.004 · Cited by 2,210 · cited 2×
“Obviously, patients treated with exenatide showed a greater improvement in acute -cell function, which is considered to be the result of binding to the -cell GLP-1 receptor (13).”
BackgroundResultKahn, S. E. (2003) · Diabetologia · doi:10.1007/s00125-002-1009-0 · Cited by 2,166 · cited 2×
“3 ype 2 diabetes mellitus is characterized by beta-cell dysfunction against a background of obesity-related insulin resistance (1).”
BackgroundDeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559 · cited 4×
“These studies also showed amelioration of surrogate measures of beta-cell function (4-6; 8).”
BackgroundResultInfluentialBuse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2628 · Cited by 1,346
Zander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297
Kendall, D. M., Riddle, M. C., Rosenstock, J., Zhuang, D., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1083 · Cited by 1,177
Self-citationCauter, E. V., Mestrez, F., Sturis, J., & Polonsky, K. S. (1992) · Diabetes · doi:10.2337/diab.41.3.368 · Cited by 890
Cited by
Items 201–300 of 388
Gastaldelli, A., Brodows, R. G., & D'Alessio, D. (2014) · Clinical Endocrinology · doi:10.1111/cen.12199 · Cited by 24
Nauck, M. A., & Smith, U. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2009.03.002 · Cited by 30
Self-citationBlevins, T., Han, J., Nicewarner, D., Chen, S., Oliveira, J. H. A., & Aronoff, S. (2010) · Postgraduate Medicine · doi:10.3810/pgm.2010.05.2149 · Cited by 23
Cobble, M. E. (2012) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-4-8 · Cited by 26
Muskiet, M. H. A., Bunck, M. C. M., Heine, R. J., Cornér, A., Yki‐Järvinen, H., Eliasson, B., Joles, J. A., Diamant, M., Tonneijck, L., & van Raalte, D. H. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.05.001 · Cited by 23
“Diabetes Res Clin Pract Page: 4/14 detailed design and methods were published previously.(8) In brief, 69 Caucasian T2DM patients (male and female, age 30-75 years, HbA1c 48-80 mmol/mol [6.”
MethodInfluentialSelf-citationThe required beta cell research for improving treatment of type 2 diabetes
Thorens, B. (2013) · Journal of Internal Medicine · doi:10.1111/joim.12096 · Cited by 26
Unger, J. (2010) · Mayo Clinic Proceedings · doi:10.4065/mcp.2010.0470 · Cited by 23
Dar, S., Tahrani, A. A., & Piya, M. K. (2015) · Practical Diabetes · doi:10.1002/pdi.1978 · Cited by 28
Targeting Type 1 Diabetes: Selective Approaches for New Therapies
Sheehy, D. F., Quinnell, S. P., & Vegas, A. J. (2019) · Biochemistry · doi:10.1021/acs.biochem.8b01118 · Cited by 24
Incretin-Based Therapy and the Quest for Sustained Improvements in β-Cell Health
Drucker, D. J. (2011) · Diabetes Care · doi:10.2337/dc11-0986 · Cited by 25
Derosa, G., Ragonesi, P. D., Carbone, A., Fogari, E., D’Angelo, A., Cicero, A. F. G., & Maffioli, P. (2013) · Pharmacological Research · doi:10.1016/j.phrs.2013.04.005 · Cited by 22
RetractedDeFronzo, R. A., Triplitt, & Cersosimo (2010) · Vascular Health and Risk Management · doi:10.2147/vhrm.s4852 · Cited by 27
Freeman, J. S. (2010) · Mayo Clinic Proceedings · doi:10.4065/mcp.2010.0467 · Cited by 24
Sadhu, A., Schwartz, S. S., & Herman, M. E. (2015) · Endocrine Practice · doi:10.4158/ep14569.ra · Cited by 23
Ji, Q. (2017) · Clinical Therapeutics · doi:10.1016/j.clinthera.2017.03.013 · Cited by 24
Derosa, G., Cicero, A. F. G., Franzetti, I., Querci, F., Carbone, A., Piccinni, M. N., D’Angelo, A., Fogari, E., & Maffioli, P. (2013) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2012.0272 · Cited by 23
Peng, H., Want, L. L., & Aroda, V. R. (2016) · Current Diabetes Reports · doi:10.1007/s11892-016-0728-4 · Cited by 20
Liu, F., Dong, J., Yang, Q., Xue, X., Ren, Z., Gan, Y., & Liao, L. (2015) · Journal of Diabetes · doi:10.1111/1753-0407.12200 · Cited by 20
Hunt, B., Ye, Q., Valentine, W. J., & Ashley, D. (2017) · Diabetes Therapy · doi:10.1007/s13300-016-0219-2 · Cited by 22
Retnakaran, R. R., Ye, C., Emery, A., Kramer, C. K., & Zinman, B. (2022) · Nature Communications · doi:10.1038/s41467-022-33867-9 · Cited by 21
Abdul-Ghani, M., Williams, K., Kanat, M., Altuntaş, Y., & DeFronzo, R. (2013) · Journal of Endocrinological Investigation · doi:10.3275/8367 · Cited by 22
The effects of GLP-1 analogues on pre-diabetes of the children
Zhou, Q., Wang, Z.-Y., Zhao, H.-F., & Wang, S. (2017) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2017.4129 · Cited by 20
Anyanwagu, U., Mamza, J., Donnelly, R., & IDRIS, I. R. (2016) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2016.09.002 · Cited by 23
Diabetes: glycaemic control in type 2 (drug treatments).
Gorter, K. J., de Laar, F. A. V., Janssen, P. G. H., Houweling, S. T., & Rutten, G. E. H. M. (2012) · Europe PMC (PubMed Central) · Cited by 20
Gluco-Incretins Regulate Beta-Cell Glucose Competence by Epigenetic Silencing of Fxyd3 Expression
Vallois, D., Niederhäuser, G., Ibberson, M. R., Nagaray, V., Marselli, L., Marchetti, P., Chatton, J., & Thorens, B. (2014) · PLoS ONE · doi:10.1371/journal.pone.0103277 · Cited by 21
Focus on Incretin-Based Therapies: Targeting the Core Defects of Type 2 Diabetes
Jellinger, P. S. (2011) · Postgraduate Medicine · doi:10.3810/pgm.2011.01.2245 · Cited by 21
Add-on therapies to metformin for type 2 diabetes
Shomali, M. E. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.542150 · Cited by 19
Choice of early treatment regimen and impact on β-cell preservation in type 2 diabetes
Mudaliar, S. R. D. (2013) · International Journal of Clinical Practice · doi:10.1111/ijcp.12154 · Cited by 19
Mari, A., Prato, S. D., Ludvik, B. H., Miličević, Z., de la Peña, A., Shurzinske, L., Karanikas, C. A., & Pechtner, V. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12671 · Cited by 18
Engineering a novel protease-based Exendin-4 derivative for type 2 antidiabetic therapeutics
Zhong, X., Yang, S., Liu, T., Ji, S., Hu, J., & Li, H. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.03.050 · Cited by 18
After avandia: the use of antidiabetic drugs in patients with heart failure.
Khalaf, K. I., & Taegtmeyer, H. (2012) · Europe PMC (PubMed Central) · Cited by 26
Bennett, W. L., Balfe, L. M., & Faysal, J. M. (2012) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2012.18.s1-a.1 · Cited by 17
International Diabetes Center Treatment of Type 2 Diabetes Glucose Algorithm
Simonson, G., Cuddihy, R. M., Reader, D., & Bergenstal, R. M. (2011) · Diabetes Management · doi:10.2217/dmt.10.22 · Cited by 21
Watada, H., Shiramoto, M., Irie, S., Terauchi, Y., Yamada, Y., Shiosakai, K., Myobatake, Y., & Taguchi, T. (2018) · Journal of Diabetes Investigation · doi:10.1111/jdi.12849 · Cited by 16
Tran, S., Kramer, C. K., Zinman, B., Choi, H., & Retnakaran, R. R. (2017) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00374.2017 · Cited by 17
Preclinical and Clinical Data on Extraglycemic Effects of GLP-1 Receptor Agonists
Gallwitz, B. (2009) · The Review of Diabetic Studies · doi:10.1900/rds.2009.6.247 · Cited by 17
Emerging Role of Caveolin-1 in GLP-1 Action
Puddu, A., & Maggi, D. C. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.668012 · Cited by 16
Early use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in Type 2 diabetes
Ross, S. A., & Ballantine, J. (2013) · Current Medical Research and Opinion · doi:10.1185/03007995.2013.837817 · Cited by 16
Sjöstrand, M., Carlson, K., Arnqvist, H. J., Guðbjörnsdóttir, S., Landin‐Olsson, M., Lindmark, S., Nyström, L., Svensson, M. K. E., Eriksson, J. W., & Bolinder, J. (2013) · Journal of Internal Medicine · doi:10.1111/joim.12116 · Cited by 16
Clinical effects of once-weekly exenatide for the treatment of type 2 diabetes mellitus
Ryan, G. J., Moniri, N. H., & Smiley, D. D. (2013) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp120168 · Cited by 19
Noninsulin pharmacological management of type 1 diabetes mellitus
Garg, V. (2011) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.83053 · Cited by 21
“[43] Although data are still limited and the effect of incretin-based agents seems to disappear early after discontinuation of treatment, it is conceivable that this class of drugs may preserve beta-cell function in human beings, at least for up to 1 year of continuous treatment.[43]”
BackgroundZhong, X., Zhang, T., Liu, Y., Wei, X., Zhang, X., Qin, Y., Jin, Z., Chen, Q., Ma, X., Wang, R., et al. (2015) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2015.05.048 · Cited by 16
“8 Seventeen distinct randomized controlled trials (5,874 adult individuals)([9,10,17-31]) were included in”
BackgroundPawaskar, M. D., Li, Q., Hoogwerf, B. J., Reynolds, M. W., Faries, D. E., Engelman, W., Bruhn, D. F., & Bergenstal, R. M. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01581.x · Cited by 15
Role and development of GLP-1 receptor agonists in the management of diabetes.
Chia, C. W., & Egan, J. M. (2009) · Europe PMC (PubMed Central) · Cited by 15
Disease modifying therapies in type 1 diabetes: Where have we been, and where are we going?
Lord, S. M., & Greenbaum, C. J. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.02.002 · Cited by 16
Moon, J. H., Choe, H. J., & Lim, S. K. (2024) · Journal of Diabetes Investigation · doi:10.1111/jdi.14221 · Cited by 15
“Longitudinal studies, including a 1 year treatment comparison between exenatide and insulin glargine, have demonstrated exenatide ’ s superior ef fi cacy in improving b -cell function, using an arginine-stimulated hyperglycemic clamp 76,77 .”
BackgroundIonut, V., Castro, A. V. B., Woolcott, O. O., Stefanovski, D., Iyer, M. S., Broussard, J. L., Burch, M., Elazary, R., Kolka, C. M., Mkrtchyan, H., et al. (2014) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00244.2014 · Cited by 13
Inagaki, N., Ueki, K., Yamamura, A., Saitô, H., & Imaoka, T. (2011) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2011.00137.x · Cited by 16
Kim, S. W. (2010) · Korean Diabetes Journal · doi:10.4093/kdj.2010.34.6.331 · Cited by 14
Paul, S., Best, J., Klein, K., Han, J., & Maggs, D. (2012) · Diabetes, obesity and metabolism · doi:10.1111/j.1463-1326.2012.01609.x · Cited by 15
Pathogenesis of type 2 diabetes mellitus
DeFronzo, R. A. (2015) · Wiley eBooks · doi:10.1002/9781118387658.ch25 · Cited by 35
Quan, H., Zhang, H., Wei, W., Fang, T., Chen, D., & Chen, K. (2017) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2017.4863 · Cited by 13
Pan, H., Su, Y., Xie, Y., Wang, W., Qiu, W., Chen, W., Lu, W., Lu, Z., Wang, W., & Shang, A. (2020) · Artificial Cells Nanomedicine and Biotechnology · doi:10.1080/21691401.2020.1770268 · Cited by 13
Revolutionizing type 1 diabetes management: Exploring oral insulin and adjunctive treatments
Nabi‐Afjadi, M., Ostadhadi, S., Liaghat, M., Pasupulla, A. P., Masoumi, S., Aziziyan, F., Zalpoor, H., Abkhooie, L., & Tarhriz, V. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116808 · Cited by 15
Treatment of diabetes with glucagon-like peptide-1 gene therapy
Riedel, M. J., & Kieffer, T. J. (2010) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2010.532786 · Cited by 13
Htike, Z., Khunti, K., & Davies, M. (2012) · Diabetes Therapy · doi:10.1007/s13300-012-0003-x · Cited by 12
Kondo, Y., Satoh, S., Osada, U. N., & Terauchi, Y. (2015) · Endocrine Journal · doi:10.1507/endocrj.ej15-0206 · Cited by 16
Nauck, M. A., & Vardarli, I. (2010) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2010.00004.x · Cited by 12
Pawaskar, M. D., Zagar, A. J., Sugihara, T., & Shi, L. (2010) · Journal of Medical Economics · doi:10.3111/13696998.2010.544797 · Cited by 13
Type 2 diabetes mellitus and the cardiometabolic syndrome: impact of incretin-based therapies
Schwartz, S. S. (2010) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmsott.s11389 · Cited by 16
“57 In addition, 1-year treatment with exenatide demonstrated improvement in glucose-and arginine-stimulated insulin secretion 58 while 3-year treatment showed sustained HOMA-B improvement.”
Pawaskar, M., Li, Q., & Reynolds, M. W. (2012) · Current Medical Research and Opinion · doi:10.1185/03007995.2012.686901 · Cited by 12
Implications of incretin‐based therapies on cardiovascular disease
Rotz, M., Ganetsky, V. S., Sen, S., & Thomas, T. F. (2015) · International journal of clinical practice · doi:10.1111/ijcp.12572 · Cited by 11
Incretin-based therapy and pancreatic beta cells
Chon, S., Riveline, J., Blondeau, B., & Gautier, J. (2014) · Diabetes & Metabolism · doi:10.1016/j.diabet.2014.05.003 · Cited by 13
Gene expression signature: a powerful approach for drug discovery in diabetes
Sithara, S., Crowley, T. M., Walder, K. R., & Aston‐Mourney, K. (2016) · Journal of Endocrinology · doi:10.1530/joe-16-0515 · Cited by 12
“2015a), however, human studies suggest no long-term effects (Bunck et al. 2009) • Side effects such as nausea, vomiting and diarrhoea (Dungan et al.”
BackgroundTargeting Islets: Metabolic Surgery Is More than a Bariatric Surgery
Chen, X., Zhang, J., & Zhou, Z. (2019) · Obesity Surgery · doi:10.1007/s11695-019-03979-1 · Cited by 14
Beta‐cell function in type 2 diabetes ( T2DM ): Can it be preserved or enhanced?
Kassem, L. S., Rajpal, A., Barreiro, M. V. E., & Ismail‐Beigi, F. (2023) · Journal of Diabetes · doi:10.1111/1753-0407.13446 · Cited by 16
Podobnik, J., & Prentice, K. J. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16154 · Cited by 15
Differential effects of prandial and non-prandial GLP-1 receptor agonists in type 2 diabetes therapy
Davidson, J. A. (2015) · Postgraduate Medicine · doi:10.1080/00325481.2015.1096743 · Cited by 12
Long-term studies of treatments for type 2 diabetes
Caballero, A. E. (2016) · Postgraduate Medicine · doi:10.1080/00325481.2017.1265417 · Cited by 12
Bolli, G. B., Lucidi, P., Porcellati, F., & Fanelli, C. G. (2011) · Diabetes Care · doi:10.2337/dc11-s224 · Cited by 12
“Although the risk for hypoglycemia is higher with basal insulin than with GLP-1 analogs (14,15), the absolute events are”
BackgroundLiraglutide Therapy in a Prediabetic State: Rethinking the Evidence
Papaetis, G. S. (2019) · Current Diabetes Reviews · doi:10.2174/1573399816666191230113446 · Cited by 11
Schwanstecher, C., & Schwanstecher, M. (2011) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-17214-4_1 · Cited by 13
Östenson, C., Matthaei, S., Reaney, M., Krarup, T., Guerci, B., Kiljański, J., Salaun-Martin, C., Sapin, H., Bruhn, D., Mathieu, C., et al. (2013) · Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy · doi:10.2147/dmso.s41827 · Cited by 14
Shi, X., Shi, Y., Chen, N., Lin, M., Su, W., Zhang, H., Liu, C., Song, H., Xiao, F., Huang, P., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-02631-1 · Cited by 10
Rosenstock, J., Robins, D. A., Duffin, K. L., Wilson, J. M., Lin, Y., Banerjee, H., Eyde, S., KAZDA, C. M., Кониг, М., & Mather, K. J. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70022 · Cited by 13
Hussain, M., Atif, M. A., Tunio, A. G., Ali, B., Akhtar, L., & Shaikh, G. S. (2016) · PubMed · Cited by 18
Salari, P., Nikfar, S., & Abdollahi, M. (2011) · International Journal of Pharmacology · doi:10.3923/ijp.2011.749.756 · Cited by 8
Gastaldelli, A., Balas, B., Ratner, R. E., Rosenstock, J., Charbonnel, B. H., Bolli, G. B., Boldrin, M. N., & Balena, R. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12192 · Cited by 10
Therapeutic Options that Provide Glycemic Control and Weight Loss for Patients with Type 2 Diabetes
Blevins, T. (2010) · Postgraduate Medicine · doi:10.3810/pgm.2010.01.2111 · Cited by 8
Kondo, Y., Satoh, S., & Terauchi, Y. (2024) · Diabetology International · doi:10.1007/s13340-024-00717-6 · Cited by 8
Evidence-Based Practice Use of Incretin-Based Therapy in the Natural History of Diabetes
Schwartz, S. S. (2014) · Postgraduate Medicine · doi:10.3810/pgm.2014.05.2757 · Cited by 9
Serum Levels of Incretin Hormones – GLP-1 and GIP in Patients with Type 1 Diabetes Mellitus
Stanchev, P. E., Orbetzova, M. M., Terzieva, D. D., Davcheva, D. M., Iliev, D. A., Petrov, S. V., Koleva, D. I., & Nonchev, B. (2019) · Folia Medica · doi:10.2478/folmed-2018-0056 · Cited by 7
Acute Hyperglycemia Induced by Hyperglycemic Clamp Affects Plasma Amyloid-β in Type 2 Diabetes
Rolandsson, O., Tornevi, A., Steneberg, P., Edlund, H., Olsson, T., Andréasson, U., Zetterberg, H., & Blennow, K. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-230628 · Cited by 8
New Incretin Hormonal Therapies in Humans Relevant to Diabetic Cats
Reusch, C. E., & Padrutt, I. (2013) · Veterinary Clinics of North America Small Animal Practice · doi:10.1016/j.cvsm.2012.11.003 · Cited by 9
Bi, Y., Li, X., Yang, D., Hao, Y., Liang, H., Zhu, D., & Weng, J. (2011) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2011.00187.x · Cited by 8
β-cell preservation and regeneration for diabetes treatment: where are we now?
Karadimos, M., Kapoor, A., Khattabi, I. E., & Sharma, A. (2012) · Diabetes Management · doi:10.2217/dmt.12.21 · Cited by 10
Managing type 2 diabetes: new policy and interventions
Gillibrand, W. P., Holdich, P., & Covill, C. (2009) · British Journal of Community Nursing · doi:10.12968/bjcn.2009.14.7.43072 · Cited by 6
Lamb, I. M., White, A. D., Willard, F. S., Chalmers, M. J., & Xiao, J. (2025) · Journal of Proteome Research · doi:10.1021/acs.jproteome.5c00079 · Cited by 6
Iványi, T., Fövényi, J., Faludi, P., Han, J., MacConell, L., Wille, S. A., & Kiljanski, J. I. (2012) · Clinical Therapeutics · doi:10.1016/j.clinthera.2012.04.022 · Cited by 6
Antidiabetika: Gewichtsreduktion als wünschenswerter Begleiteffekt
Wirth, A. G. (2011) · Der Internist · doi:10.1007/s00108-011-2811-x · Cited by 6
Asai, S., Ohta, A., Kato, H., Sada, Y., Nagai, Y., Kondo, A., Sasaoka, T., & Tanaka, Y. (2014) · Endocrine Journal · doi:10.1507/endocrj.ej14-0194 · Cited by 6
Grimm, M., Li, Y., Brunell, S. C., & Blasé, E. (2013) · Postgraduate medicine · doi:10.3810/pgm.2013.09.2704 · Cited by 7
Gu, N., Cho, S., Kim, J. W., Shin, D., Seol, E., Lee, H., Lim, K. S., Shin, S., Jang, I., & Yu, K. (2014) · Clinical Therapeutics · doi:10.1016/j.clinthera.2013.12.002 · Cited by 7
Htike, Z., Zaccardi, F., Chatterjee, S., Khunti, K., & Davies, M. (2016) · British Journal of Diabetes · doi:10.15277/bjd.2016.091 · Cited by 6
Chen, X., Xu, Y., Zhang, J., Shao, S., Duan, Y., Liu, P., Shen, L., Zhang, J., Zeng, J., Lin, M., et al. (2021) · Endocrine Practice · doi:10.1016/j.eprac.2021.03.015 · Cited by 6
‘Insulin should be prescribed at the outset of diagnosis of type 2 diabetes’
Kong, M., & Bickerton, A. S. T. (2011) · Practical Diabetes · doi:10.1002/pdi.1564 · Cited by 6
Potential Cardiovascular Effects of the Glucagon-like Peptide-1 Receptor Agonists
Chilton, R. (2015) · Journal of Diabetes & Metabolism · doi:10.4172/2155-6156.1000483 · Cited by 4
Intervention with Therapeutic Agents, Understanding the Path to Remission to Type 2 Diabetes
Hao, S., Umpierrez, G. E., & Vellanki, P. (2022) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2022.07.004 · Cited by 6
Quan, H., Gao, Y., Zhang, H., Fang, T., Chen, D., Lv, Z., & Chen, Y. (2014) · Molecular Medicine Reports · doi:10.3892/mmr.2014.2538 · Cited by 5
Effects of Exenatide in a Morbidly Obese Patient with Type 2 Diabetes
Kishimoto, M., & Noda, M. (2014) · Diabetes Therapy · doi:10.1007/s13300-014-0050-6 · Cited by 5
“A previous study [42] demonstrated that 1 year of exenatide treatment significantly improved b cell function and decreased body weight in the presence of similar improvements in glycemic control, when compared with insulin glargine treatment.”
Result
Metadata
- Authors
- Bunck, M. C., Diamant, M., Cornér, A., Eliasson, B., Malloy, J. L., Shaginian, R. M., Deng, W., Kendall, D. M., Taskinen, M.-R., Smith, U., Yki-Järvinen, H., & Heine, R. J.
- Affiliations
- Amsterdam UMC Location Vrije Universiteit Amsterdam (NL)
- Department of Endocrinology, Diabetes Center, VU University Medical Center, Amsterdam, the Netherlands;
- Helsinki University Hospital (FI)
- Lundberg Laboratory for Diabetes Research, Sahlgrenska University Hospital, Göteborg, Sweden;
- Amylin Pharmaceuticals, San Diego, California;
- Eli Lilly (Netherlands) (NL)
- Sahlgrenska University Hospital (SE)
- Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland;
- Eli Lilly (United States) (US)
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2009-02-05
- Volume
- 32
- Issue
- 5
- Pages
- 762-768
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC2671094
- OpenAlex
- W2148798434
- Cited by
- 388
- References
- 27
- Citations by year
- 2026: 4 · 2025: 7 · 2024: 8 · 2023: 5 · 2022: 7 · 2021: 5 · 2020: 8 · 2019: 12 · 2018: 8 · 2017: 16 · 2016: 19 · 2015: 24 · 2014: 34 · 2013: 40 · 2012: 44
- FWCI
- 46.23
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- exenatide, insulin glargine, type 2 diabetes, beta-cell function, metformin, glycemic control, HbA1c, body weight, C-peptide secretion, drug discontinuation, GLP-1 receptor agonists
- MeSH terms
- Insulin Glargine, Exenatide, Insulin Secretion, Arginine, Blood Glucose, C-Peptide, Diabetes Mellitus, Type 2, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Insulin, Kinetics, Male, Metformin, Middle Aged, Peptides, Venoms, Body Mass Index, Insulin, Long-Acting, Insulin-Secreting Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.